• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

PAS, Adult and Pediatric


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Study Pending
Application Number P170039 / PAS001
Date Current Protocol Accepted  
Study Name PAS, Adult and Pediatric
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Device Subjects Serve as Own Control
Analysis Type Descriptive
Study Population Child: 2-12 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description Prospective, nonrandomized, multi-center, safety study. This is an extended follow-up post-approval study (PAS). The study population is limited to adult and pediatric subjects who participated in the previous 12-month AI-001 IDE clinical trial and are implanted with the CUSTOMFLEX®ARTIFICIALIRIS for less than 36 months (adults) or 60 months (pediatrics).



Study Population Description The study includes the implanted subjects. There is no control arm. The postoperative outcomes are compared to their preoperative baseline.



Sample Size Up to 527 adult and pediatric eyes implanted with the CUSTOMFLEX®ARTIFICIALIRIS in the AI-001 IDE clinical trial. The sample size is based on demonstrating the cumulative device related adverse event rate was less than 5% for all adverse events in the study and, no individual adverse event should exceed a rate of 1%. The proposed sample size (527 adult and pediatric eyes) is sufficient to achieve >90% power of detecting an individual device related adverse rate with an incidence of at least 2.0%.
Data Collection The primary study outcome is to evaluate device related adverse events (AEs) postoperatively at the Month 36 (adults) or Month 60 (pediatrics).

The secondary study outcome is to evaluate the cumulative rate of intraocular lens (IOL)-related AEs at the Month 36 (adults) or Month 60 (pediatrics).

Other outcomes:

Secondary surgical interventions, implant position, device or surgery related complications, and device malfunctions or defects. Outcomes that will be evaluated include, but are not limited to:

Cumulative AEs

Endothelial cell density (ECD) changes

Device malfunction or defects

Device related complications
Follow-up Visits and Length of Follow-up 36 months postoperatively for adults and 60 months post-operatively for pediatric subjects.





PAS, Adult and Pediatric Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 11/28/2018 12/27/2018 Overdue/Received
one year report 05/30/2019 05/30/2019 On Time
18 month report 11/28/2019   Overdue
two year report 05/29/2020    
three year report 05/29/2021    
four yer report 05/29/2022    
five year report 05/29/2023    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Related Links

-
-